1.High affinity soluble ILT2 receptor: a potent inhibitor of CD8(+) T cell activation.
Ruth K MOYSEY ; Yi LI ; Samantha J PASTON ; Emma E BASTON ; Malkit S SAMI ; Brian J CAMERON ; Jessie GAVARRET ; Penio TODOROV ; Annelise VUIDEPOT ; Steven M DUNN ; Nicholas J PUMPHREY ; Katherine J ADAMS ; Fang YUAN ; Rebecca E DENNIS ; Deborah H SUTTON ; Andy D JOHNSON ; Joanna E BREWER ; Rebecca ASHFIELD ; Nikolai M LISSIN ; Bent K JAKOBSEN
Protein & Cell 2010;1(12):1118-1127
Using directed mutagenesis and phage display on a soluble fragment of the human immunoglobulin super-family receptor ILT2 (synonyms: LIR1, MIR7, CD85j), we have selected a range of mutants with binding affinities enhanced by up to 168,000-fold towards the conserved region of major histocompatibility complex (MHC) class I molecules. Produced in a dimeric form, either by chemical cross-linking with bivalent polyethylene glycol (PEG) derivatives or as a genetic fusion with human IgG Fc-fragment, the mutants exhibited a further increase in ligand-binding strength due to the avidity effect, with resident half-times (t(1/2)) on the surface of MHC I-positive cells of many hours. The novel compounds antagonized the interaction of CD8 co-receptor with MHC I in vitro without affecting the peptide-specific binding of T-cell receptors (TCRs). In both cytokine-release assays and cell-killing experiments the engineered receptors inhibited the activation of CD8(+) cytotoxic T lymphocytes (CTLs) in the presence of their target cells, with subnanomolar potency and in a dose-dependent manner. As a selective inhibitor of CD8(+) CTL responses, the engineered high affinity ILT2 receptor presents a new tool for studying the activation mechanism of different subsets of CTLs and could have potential for the development of novel autoimmunity therapies.
Amino Acid Sequence
;
Antigens, CD
;
chemistry
;
genetics
;
pharmacology
;
Autoimmunity
;
Biological Assay
;
Cell Line
;
Cytotoxicity, Immunologic
;
genetics
;
immunology
;
Dose-Response Relationship, Immunologic
;
Humans
;
Immunoglobulins
;
immunology
;
metabolism
;
Immunologic Factors
;
chemistry
;
genetics
;
pharmacology
;
Kinetics
;
Leukocyte Immunoglobulin-like Receptor B1
;
Lymphocyte Activation
;
genetics
;
immunology
;
Major Histocompatibility Complex
;
genetics
;
immunology
;
Molecular Sequence Data
;
Molecular Targeted Therapy
;
Mutagenesis, Site-Directed
;
Peptide Library
;
Polyethylene Glycols
;
Protein Binding
;
genetics
;
immunology
;
Receptors, Immunologic
;
chemistry
;
genetics
;
Recombinant Fusion Proteins
;
genetics
;
metabolism
;
T-Lymphocytes, Cytotoxic
;
immunology
;
metabolism